Patents by Inventor Arianna Calcinotto

Arianna Calcinotto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BACTERIAL STRAINS FOR MEDICAL USES
    Publication number: 20220031765
    Abstract: The present invention relates to the field of bacterial strain to be used in medicine. In particular, it relates to the prevention and/or treatment of cancer or diabetes, bacterial strain is Prevotella melaninogenica.
    Type: Application
    Filed: December 2, 2019
    Publication date: February 3, 2022
    Applicant: OSPEDALE SAN RAFFAELE S.R.L.
    Inventors: Matteo Maria Salvatore BELLONE, Arianna BREVI, Arianna CALCINOTTO, Roberto FERRARESE, Filippo CANDUCCI
  • Methods of treating androgen deprivation therapy resistant prostate cancer
    Patent number: 11168134
    Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: November 9, 2021
    Assignees: FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR), THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Andrea Alimonti, Arianna Calcinotto, Johann de Bono
  • ENHANCEMENT OF PROSTATE CANCER TREATMENT
    Publication number: 20200095314
    Abstract: The present invention provides a method of treatment of prostate cancer, comprising administering a therapeutically effective amount of an inhibitor of IL-23 and/or an inhibitor of IL-23R to a mammalian patient in need thereof. The prostate cancer may be castration resistant prostate cancer (CRPC). The inhibitor may, for example, be an anti-IL-23 antibody, such as risankizumab, guselkumab or tildrakizumab. The method of treatment may further comprise administration of androgen deprivation therapy, such as enzalutamide. Also provided is a method of predicting the development of resistance to androgen deprivation therapy (ADT) in a prostate cancer in a mammalian patient and a related screening method.
    Type: Application
    Filed: September 18, 2019
    Publication date: March 26, 2020
    Applicants: Fondazione per l'Istituto Oncologico di Ricerca (IOR), The Institute of Cancer Research: Royal Cancer Hospital
    Inventors: Andrea Alimonti, Arianna Calcinotto, Johann de Bono